Of the approximately 612,000 cancer deaths expected in the United States in 2024, 90% will be caused by anticancer drugs.
Oregon Therapeutics and Lantern Pharma are using an artificial intelligence (AI)-driven strategic strategy to optimize the development of protein disulfide isomerase (PDI) inhibitor candidates for a variety of novel targeted cancer indications. We have concluded a partnership.
XCE853 is being developed by Oregon for a variety of indications, including drug-resistant ovarian and pancreatic cancers, certain blood cancers, and several childhood cancers, including central nervous system cancers.
Cancer is expected to cause nearly 612,000 deaths in the United States in 2024, 90% of which will be due to resistance to anticancer drugs.
Under the terms of the agreement, Lantern will receive equivalent intellectual property (IP) co-ownership and drug development rights in XCE853’s newly discovered biomarkers, novel indications, and pharmacological use strategies, while Oregon will receive We are entitled to financial benefits arising from the licensing of XCE853. Set the background IP to Lantern.
Both companies have the right to receive additional financial benefits from licensing their joint IP to third parties.
As part of the agreement, Lantern will leverage its proprietary RADR AI platform to identify biomarkers and efficacy-related signatures for XCE853 across solid tumors to help improve precision.
RADR has a growing library of over 60 million data points from a wide variety of biological measurements and oncology experiments, focusing on questions central to real-world cancer drug development. It also features over 200 machine learning algorithms.
The collaboration also aims to identify tumor-based responses and resistance mechanisms to XCE853 to overcome resistance and expand the use of the candidate in addition to XCE853’s cancer treatment indications.
Panna Sharma, CEO and President of Lantern, said: “Our AI platform is poised to make very important, patient-centered decisions about the clinical future of (XCE853).”
“Our team efficiently selects among ideal development options and efficiently de-risks future clinical development decisions,” said Mark Henry Pity, CEO of Oregon. We look forward to mitigating this.”
